Delving into the Latest Updates on Degarelix Acetate with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Degarelix acetate (USAN), Degarelix acetate hydrate, UGLYPEPTIDE-1

+ [9]

Target

GnRHR

Action

antagonists

Mechanism

GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Castration-sensitive prostate cancerHormone-dependent prostate cancerProstatic Cancer+ [4]

Inactive Indication

Advanced Prostate CarcinomaCardiovascular DiseasesCoronary Artery Disease+ [10]

Originator Organization

FERRING BV

Active Organization

Ferring Pharmaceuticals, Inc.

Ferring Pharmaceuticals A/SFerring Pharmaceuticals Pvt Ltd.

+ [4]

Inactive Organization

Ferring Pharmaceuticals SARentschler Biotechnologie Beteiligungs GmbHFerring Pharmaceuticals Korea Co., Ltd.

+ [2]

License Organization

Astellas Pharma, Inc.

Pfizer Inc.Ferring Holding SA

Drug Highest PhaseApproved

First Approval Date

United States (24 Dec 2008),

Prostatic Cancer

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC84H109ClN18O19

InChIKeyQMBXFMRFTMPFEY-YECCWIQASA-N

CAS Registry934246-14-7

Sequence Code 26246295

Source: *****

The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).

Start Date29 Jul 2026

Sponsor / Collaborator

Baptist Health South Florida, Inc.

[+1]

CTIS2024-518120-68-01

/ Not yet recruitingPhase 2IIT

Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial

Start Date01 Jun 2026

Sponsor / Collaborator-

ChiCTR2600121819

/ Not yet recruitingNot ApplicableIIT

Triplet therapy combined with robot-assisted cytoreductive prostatectomy in high-volume metastatic prostate cancer: a prospective, multicentre, randomized controlled trial

Start Date06 Apr 2026

Sponsor / Collaborator

The Seventh Affiliated Hospital of Sun Yat sen University (Shenzhen)

100 Clinical Results associated with Degarelix Acetate

Login to view more data

100 Translational Medicine associated with Degarelix Acetate

Login to view more data

100 Patents (Medical) associated with Degarelix Acetate

Login to view more data

402

Literatures (Medical) associated with Degarelix Acetate

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer

Article

Author: Högerman, Mikael ; Anttinen, Mikael ; Ettala, Otto ; Nurminen, Pertti ; Mäkelä, Pietari ; Sainio, Teija ; Virtanen, Ilari

BACKGROUND:

Thermal ablation is a minimally invasive treatment for localized prostate cancer (PCa). MRI-guided transurethral ultrasound ablation (TULSA) enables precise, temperature-controlled therapy, but its 3 cm ablation radius may limit coverage in large prostates or capsule-adjacent tumors. Neoadjuvant androgen deprivation therapy (nADT) may improve treatment feasibility by reducing prostate and tumor size.

METHODS:

In this prospective, single-arm pilot study (NCT05917860), 15 treatment-naïve patients with organ-confined, intermediate-risk ISUP 2-3 PCa and at least one biopsy-concordant PI-RADS ≥ 3 lesion received 3-month nADT with degarelix before whole-gland TULSA. Multiparametric MRI was performed at baseline and monthly thereafter to assess prostate and lesion volumes, tumor-capsule relationship, and urethra-capsule distance.

RESULTS:

All patients completed nADT. Across 27 PI-RADS ≥ 3 lesions, four patients had unifocal disease, and 11 had multifocal disease (2-3 lesions). Twenty lesions were ISUP Grade Group 2 and three were Grade Group 3. PSA declined by 87% (-7.6 ng/mL; 95% CI. -9.7 to -5.7; p < 0.001), and all patients achieved castrate testosterone levels. Prostate volume decreased by 26% (-15 mL; 95% CI. -20 to -12; p < 0.001), index lesion volume by 69% (-0.8 mL; 95% CI. -1.2 to -0.5; p < 0.001), and index-lesion capsule contact length by 40% (-5 mm; 95% CI. -7 to -4; p < 0.001). Capsule bulging resolved in four of seven patients, and urethra-capsule distance decreased to ≤ 30 mm in all six patients with a baseline distance > 30 mm.

CONCLUSION:

Short-term nADT with degarelix was associated with significant changes in prostate and tumor morphology. Future studies should determine whether these changes improve TULSA outcomes.

01 Oct 2026·UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study

Article

Author: Wallis, Christopher J D ; Mundra, Vatsala ; Porika, Aamuktha ; Titus, Renil S ; Riveros, Carlos ; Efstathiou, Eleni ; Singh, Amar ; Nguyen, David-Dan ; Satkunasivam, Raj ; Ranganathan, Sanjana ; Patel, Kershaw V ; Kaushik, Dharam ; Velasquez, Eusebio Luna

PURPOSE:

Androgen deprivation therapy (ADT) is standard treatment for metastatic hormone-sensitive prostate cancer (mHSCaP). Patients receive LHRH-agonists (LHRH-AG: leuprolide, goserelin or triptorelin) or LHRH-antagonists (LHRH-AN: degarelix or relugolix) with intensification with androgen receptor pathway inhibitors, with or without chemotherapy. Given ongoing concerns about cardiovascular risk, we used real-world data from TriNetX to compare the incidence of major adverse cardiovascular events (MACE) between patients receiving LHRH-AG vs. LHRH-AN.

MATERIALS AND METHODS:

We included adult patients with mHSCaP who received either an LHRH-AG or LHRH-AN. The composite primary outcome was MACE (defined as myocardial infarction (MI), stroke, or all-cause mortality). Secondary outcomes were MI, stroke, and all-cause mortality. Patients were 1:1 propensity-score matched (PSM). Kaplan-Meier analysis reporting hazard ratios (HR) and 95% confidence intervals (CI) for the outcomes was conducted. We conducted a subgroup analysis to assess the effect of intensification of therapy. Exploratory analyses were conducted to assess HR of outcomes and new-onset metabolic comorbidities (diabetes mellitus, insulin use, hypertension, and dyslipidemia) amongst patients without cardiovascular risk factors.

RESULTS:

Before PSM, there were 27,051 in LHRH-AG and 3,339 in LHRH-AN cohorts. After PSM, 3,329 patients in each cohort were compared. Compared to LHRH-AN, LHRH-AG was associated with a decreased risk of MACE (hazard ratio [HR] = 0.86, 95% CI: 0.79-0.93), MI (HR = 0.80, 95% CI: 0.66-0.97), and any-cause mortality (HR = 0.85, 95% CI: 0.78-0.93). Treatment intensification did not modify the association between MACE outcomes and LHRH-AG vs. LHRH-AN.

CONCLUSIONS:

Using real-world data, LHRH-AG was associated with a decreased risk of experiencing MACE. Among those undergoing intensification of therapy, there was no difference in MACE risk associated with LHRH-AG vs. LHRH-AN.

01 Oct 2026·Journal of Minimally Invasive Gynecology

Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis

Review

Author: Farrow, Monique ; Denny, Kathryn ; Hsu, Richard ; Han, Esther S ; Pacis, Michelle ; Swartz, Sarah

STUDY OBJECTIVE:

To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists vs placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.

DESIGN:

Systematic review and meta-analysis of phase 3 randomized, double-blind, placebo-controlled trials of oral GnRH antagonists in people with moderate-to-severe endometriosis-associated pain, with dual screening, standardized data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2 tool.

SETTING:

Multicenter phase 3 clinical trials conducted in outpatient gynecology and reproductive health settings across North America, Europe, and other international sites, identified through electronic databases and trial registries from inception through October 2025.

PATIENTS:

A total of 2060 participants with surgically or imaging-diagnosed endometriosis and moderate-to-severe baseline pain, with mean ages of 31 to 35 years, enrolled in five phase 3 trials (ELARIS, SPIRIT 1 and 2, and EDELWEISS-3).

INTERVENTIONS:

The included trials evaluated three oral GnRH antagonist regimens: elagolix 200 mg twice daily without add‑back, relugolix 40 mg once daily combination therapy, and linzagolix 200 mg once daily with add-back. Add-back and combination therapy were defined as co‑administration of estradiol 1 mg and norethindrone acetate 0.5 mg once daily. Each regimen was compared with a matching placebo for treatment durations up to 24 weeks.

MEASUREMENTS AND MAIN RESULTS:

Primary outcomes were binary responder rates for dysmenorrhea and non-menstrual pelvic pain, defined by prespecified reductions in daily pain scores with stable or reduced analgesic use. Fixed-effects meta-analysis with inverse-variance weighting yielded a pooled risk ratio of 3.06 (95% CI, 2.76-3.39; p <.001) and a number needed to treat (NNT) of 2 (95% CI, 2-3) for dysmenorrhea responders, and a pooled risk ratio of 1.53 (95% CI, 1.40-1.67; p <.001) and NNT of 5 (95% CI, 4-7) for non-menstrual pelvic pain responders, with no statistical heterogeneity (I² = 0%) for either outcome. Drug-level pooled risk ratios for dysmenorrhea were 3.49 (95% CI, 2.93-4.16) for elagolix 200 mg twice daily, 3.11 (95% CI, 2.32-4.17) for linzagolix 200 mg with add-back, and 2.61 (95% CI, 2.22-3.07) for relugolix combination therapy; corresponding pooled risk ratios for non-menstrual pelvic pain were 1.54 (95% CI, 1.31-1.80), 1.52 (95% CI, 1.15-2.01), and 1.52 (95% CI, 1.32-1.74), respectively. Bucher-adjusted indirect comparisons did not show robust differences in efficacy between agents for either pain domain, although elagolix was associated with a statistically significant higher dysmenorrhea response than relugolix combination therapy (risk ratio, 1.34; 95% CI, 1.05-1.70; p = .017).

CONCLUSION:

Oral GnRH antagonists provide consistent, significant, and clinically meaningful reductions in dysmenorrhea and non-menstrual pelvic pain compared with placebo, with low heterogeneity across trials and similar efficacy among elagolix, relugolix combination therapy, and linzagolix with add-back, supporting their use as effective second-line therapy for endometriosis-associated pain.

8

News (Medical) associated with Degarelix Acetate

28 Apr 2026

·jymedtech.com

JYMed Peptide Secures FDA Completeness Assessment for Second Semaglutide DMF

JYMed Peptide recently announced that an additional Drug Master File (DMF) for its Semaglutide active pharmaceutical ingredient (API), DMF No. 041090, has successfully passed the U.S. Food and Drug Administration’s Completeness Assessment (CA) and is now listed as “Available for Reference.” This new Semaglutide DMF Available for Reference further strengthens JYMed Peptide’s FDA compliance track record, following previous regulatory achievements for Degarelix Acetate, Liraglutide, and the company’s first Semaglutide DMF. Passing the Completeness Assessment confirms that the DMF meets the FDA’s foundational regulatory requirements, allowing formulation customers to reference it as a reliable compliance option for regulatory submissions. This helps lower the barrier for joint filings and accelerates global market collaboration. With this milestone, JYMed Peptide now offers two referenceable Semaglutide DMFs, providing global formulation partners with greater flexibility, expanded API sourcing options, and stronger support for joint filings and international market development. The listing of DMF No. 041090 reinforces JYMed Peptide’s competitive position in the rapidly growing GLP-1 therapeutic segment. It also reflects the company’s continued commitment to building a robust international regulatory platform and supporting customers in accelerating generic drug development. Looking ahead, JYMed Peptide will continue expanding its global regulatory footprint, leveraging its growing portfolio of certifications and compliance capabilities to help partners streamline development, enter new markets, and achieve sustainable, high-quality growth. JYMed Peptide is a high-tech enterprise specializing in the peptide sector, with business activities covering peptide API and formulation development, manufacturing, and sales; one-stop peptide CDMO services; cosmetic peptide ingredient development and manufacturing; and custom peptide synthesis services. The company is committed to becoming a leading global provider of peptide solutions, delivering high-quality, compliant products and services to pharmaceutical and cosmetic customers worldwide.

05 Jan 2026

·www.fiercebiotech.com

Teverelix: A New Direction in Prostate Cancer and Urologic Health

None\n Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer. Yet for years, the mainstay treatments for this condition, namely GnRH agonists have themselves been associated with CV risks, especially in men already vulnerable to heart disease.Meanwhile, millions of men experience acute urinary retention (AUR) a sudden, painful inability to urinate often caused by an enlarged prostate and face limited non-surgical options to prevent it from coming back.Teverelix, a novel investigational therapy being developed by Medicus Pharma could offer a new approach to both of these persistent men’s health challenges.How Teverelix WorksTeverelix is a GnRH antagonist, which means it binds to gonadotropin-releasing hormone receptors in the pituitary gland, preventing the release of two hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This rapidly reduces testosterone levels an important step in slowing the growth of prostate cancer.Importantly, Teverelix also consistently suppresses FSH, which is under increasing study for its possible role in cardiovascular and metabolic health. This aspect of Teverelix’s mechanism could help patients with elevated CV risk, a population underserved by current therapies.Why a New Therapy Is NeededWhile other GnRH antagonists like degarelix (injectable) and relugolix (oral) are on the market, they have limitations and neither is currently approved specifically for prostate cancer patients with high CV risk.In the AUR space, the standard of care involves emergency catheterization and bladder decompression, followed by use of alpha blockers and 5-alpha-reductase inhibitors (5-ARIs). However, adherence to these chronic therapies can be poor, and side effects including sexual dysfunction and mood changes can be persistent. Further, 5-ARIs take a significant amount of time to shrink the prostate.What Makes Teverelix DifferentTeverelix has the potential to become the first GnRH antagonist specifically developed for prostate cancer patients with high cardiovascular risk. Its target label will focus on this subpopulation.In AUR, Teverelix may become the first pharmacologic therapy aimed at preventing recurrence after a first episode a significant innovation in an area that currently offers limited approved solutions for relapse prevention.Clinical Status and Regulatory PathwayTo date, Teverelix has completed around ~14 clinical studies involving over 400 patients. These trials have yielded detailed pharmacokinetic and pharmacodynamic (PK/PD) data and a consistent safety profile.Looking ahead:A Phase 2b trial is planned for 2026 to establish the optimal dosing for a future cardiovascular outcomes study in high CV-risk prostate cancer patients.In parallel, a randomized, three arm trial will begin evaluating Teverelix for the prevention of AUR recurrence, addressing a substantial unmet need.These trials will inform pivotal studies intended to support potential future regulatory filings in both indications.A Platform for the FutureBeyond men’s health, Medicus is exploring how Teverelix could be valuable in women’s health applications, such as endometriosis, a condition where hormonal control plays a central role. Early clinical work is underway, including collaborations in emerging global innovation ecosystems.Meanwhile, the company continues to invest in AI-driven development aimed at accelerating and de-risking clinical development.Final ThoughtsTeverelix is not just another hormonal therapy. With its potential cardiovascular friendly profile, exploratory utility in benign urology, and platform potential, it represents a compelling and differentiated approach in endocrine-driven diseases.

Drug Approval

02 Jan 2026

·www.einpresswire.com

July - September 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

ADZYNMA (ADAMTS13, recombinant-krhn) Neutralizing antibodies with fatal outcome FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on November 21, 2025: FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 following Adzynma Treatment of Congenital Thrombotic Thrombocytopenic Purpura Asceniv (immune globulin intravenous, human-slra) Increased hypersensitivity reactions in patients receiving certain product lot FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on October 28, 2025: Immune Globulin Intravenous (IGIV) and/or Immune Globulin Subcutaneous (IGSC) Lots with Increased Reports of Allergic/Hypersensitivity Reactions Benlysta (belimumab) injection Severe cutaneous adverse reactions FDA is evaluating the need for regulatory action. Braftovi (encorafenib) capsules Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablet Sarcoidosis FDA is evaluating the need for regulatory action. Cabometyx (cabozantinib) tablets Cometriq (cabozantinib) capsules Lenvima (lenvatinib) capsules Thrombotic microangiopathy FDA is evaluating the need for regulatory action. Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Sarcoidosis FDA is evaluating the need for regulatory action. ELEVIDYS (delandistrogene moxeparvovec-rokl) Mesenteric vein thrombosis following product-related acute liver injury The "Warnings and Precautions" and "Adverse Reactions - Postmarketing Experience" sections of the labeling for Elevidys were updated in November 2025 to include life-threatening mesenteric vein thrombosis. FDA Safety Communication was issued on November 14, 2025: FDA Takes Action on New Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure Following Treatment with Elevidys and Revised Indication that is Limited to Ambulatory Duchenne Muscular Dystrophy Patients Firmagon (degarelix for injection) Myfembree (relugolix, estradiol, and norethindrone acetate) tablets Orgovyx (relugolix) tablets Drug interaction FDA is evaluating the need for regulatory action. Ifex (ifosfamide) injection Pregnancy, puerperium and perinatal conditions FDA is evaluating the need for regulatory action. Ogsiveo (nirogacestat) tablets Visual impairment FDA is evaluating the need for regulatory action. Orgovyx (relugolix) tablets Hypertension FDA is evaluating the need for regulatory action. Rezzayo (rezafungin for injection) Hypersensitivity The "Warnings and Precautions", "Adverse Reactions" and "Patient Counseling Information" sections of the labeling were updated in December 2025 to include information about hypersensitivity reactions, including anaphylaxis. Rezzayo labeling Septocaine (articaine hydrochloride and epinephrine injection) Mepivacaine hydrochloride injection (a particular generic product) Wrong drug administered FDA is evaluating the need for regulatory action. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

100 Deals associated with Degarelix Acetate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08635 D09400	-	L02BX02	DB06699

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Switzerland	Ferring Arzneimittel Gmbh	12 Feb 2010
Hormone-dependent prostate cancer	European Union	Ferring Pharmaceuticals A/S	17 Feb 2009
Hormone-dependent prostate cancer	Iceland	Ferring Pharmaceuticals A/S	17 Feb 2009
Hormone-dependent prostate cancer	Liechtenstein	Ferring Pharmaceuticals A/S	17 Feb 2009
Hormone-dependent prostate cancer	Norway	Ferring Pharmaceuticals A/S	17 Feb 2009
Hormone-dependent prostate cancer	United Kingdom	FERRING PHARMACEUTICALS LIMITED	17 Feb 2009
Prostatic Cancer	United States	Ferring Pharmaceuticals, Inc.	24 Dec 2008

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intermediate Atypical Prostate Carcinoma	Phase 3	United States	Ferring Pharmaceuticals A/S	28 Mar 2017
Advanced Prostate Carcinoma	Phase 3	United States	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Canada	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Czechia	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Finland	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	France	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Germany	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Greece	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Poland	Ferring Pharmaceuticals A/S	19 Apr 2016
Advanced Prostate Carcinoma	Phase 3	Russia	Ferring Pharmaceuticals A/S	19 Apr 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05617885 (CTgov)	Phase 1	Metastatic Prostate Carcinoma \| Non-metastatic prostate cancer	9	Abemaciclib+Darolutamide (Phase I Dose Level 0)	odftllbkrr = cyrqhsjkzv wxixrivjph (htlrfwppsc, jaduddshja - fjfaznbepm) View more	-	15 Oct 2026
				Abemaciclib+Darolutamide (Phase I Dose Level -1)	odftllbkrr = olmbzwmina wxixrivjph (htlrfwppsc, jkxhnyxaoq - mdgrswnvyc) View more
NCT03361735 (CTgov)	Phase 2	Castration-sensitive prostate cancer \| Metastatic Prostate Carcinoma \| Adenocarcinoma of prostate	25	Radium Ra 223 Dichloride (De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))	hqjhlfzsub(luomlxfweg) = ofqhylekcn aggyakyruh (xkgbusfbky, mctazffsbi - nlkdmgftkb) View more	-	09 Apr 2026
				Radium Ra 223 Dichloride (Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))	hqjhlfzsub(luomlxfweg) = huvhkqjvgw aggyakyruh (xkgbusfbky, hsqflvdxsg - fazwaywynj) View more
NCT04989946 (Pubmed \| J Immunother Cancer)	Phase 2	Localized Prostate Carcinoma	24	Degarelix alone	ckbgyprvfq(plmoinwsid) = qymdajlrsm zvgjrvkylh (rktvfthslz )	Positive	01 Mar 2026
				pTVG-AR followed by degarelix	pstnbgluxj(ellidgvvse) = vyqfmihgvr xebortwjqm (thmolidmxh ) View more
ASTRO2025	Not Applicable	Prostatic Cancer	296	Relugolix	xbnojpeudb(pitolpefmh) = cqbxerktrw sklksvbedn (dvbjzmhslu ) View more	Positive	27 Sep 2025
				Degarelix	xbnojpeudb(pitolpefmh) = xuowrcbbvr sklksvbedn (dvbjzmhslu ) View more
NCT03069937 (CTgov)	Phase 2	Metastatic Prostatic Adenocarcinoma \| Metastatic Prostate Carcinoma	52	Degarelix+Docetaxel	mhhsarrzet = ahhpcyhhsa fwilkjpezz (bwdpaapiby, yruvxedwfi - yqciqwgsnx) View more	-	29 Apr 2025
ARNEO (AUA2025)	Phase 2	Prostatic Cancer Neoadjuvant	89	Degarelix+Apalutamide	ootarcvfde(knbjysflym) = Patients with a high relative TV reduction did not show a better BCR-free survival during follow-up (p=0.41). Different cut-offs (≥90% vs <90%, and TV increase vs TV decrease) generated similar results (p>0.15). pcpuqepvzd (bdilfvywru ) View more	Negative	26 Apr 2025
				Degarelix+Placebo
NCT03056638 (CTgov)	Phase 3	Intermediate Atypical Prostate Carcinoma	56	stereotactic body radiosurgery (SBRT)+Degarelix (Degarelix in Conjunction With Stereotactic Body Radiosurgery)	ehsmqwuxme(oqujtfyiay) = ubobpnuovj wladitzyzp (vatkkdocty, dfgsrhmphw - qlrsnhmefd) View more	-	28 Aug 2024
				stereotactic body radiosurgery (SBRT) (Stereotactic Body Radiosurgery (SBRT))	ehsmqwuxme(oqujtfyiay) = izjmzgnisq wladitzyzp (vatkkdocty, pdhwcjqpmc - urzlaneyqj) View more
NCT03080116 (ARNEO, ENDO2023)	Phase 2	Prostatic Cancer Neoadjuvant	88	Degarelix+Placebo	jnpvznnqrm(ppbazpynsj) = pmjlevqwuz cmvcczulsl (jaipwmxbiu ) View more	Positive	05 Oct 2023
				Degarelix+Apalutamide	jnpvznnqrm(ppbazpynsj) = ntkselokrg cmvcczulsl (jaipwmxbiu ) View more
NCT02663908 (PRONOUNCE, CTgov)	Phase 3	Cardiovascular Diseases \| Advanced Prostate Carcinoma	545	Degarelix (Degarelix 240 mg/80 mg)	gedbroylco = zyryxwkpko pufezlofii (jnfqxsrrdl, ixqwviyqtv - ltwzjdokge) View more	-	29 Jun 2022
				Leuprolide (Leuprolide 22.5 mg)	gedbroylco = bycsgyankf pufezlofii (jnfqxsrrdl, acuwskvyki - rpcyksfclo) View more
NCT04397718 (HITCH, CTgov)	Phase 2	COVID-19	96	Saline (Placebo + BSC)	ngwlybznpv = jfkfktyaqr lvozjwfncl (uvpviwklgr, qbrzautkyu - zrrbxurswg) View more	-	06 Jun 2022
				Degarelix (Degarelix + BSC)	ngwlybznpv = ntqxkphrah lvozjwfncl (uvpviwklgr, mduuiifcwz - maqvzxeezp) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data